Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.60 |
| ▸ | PI4KA | P42356 | 7/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 7/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 7/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | AHCY | P23526 | 5/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580610 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28191737 | 0.77 | ADORA2A (0.34) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL667204 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28413958 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25325575 | 0.75 | ADORA2A (0.33) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9074153 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL13007709 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1357265 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11908593 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8069211 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922266-B1 | TOLL-LIKE RECEPTOR 7 OR 8 AGONIST-CHOLESTEROL COMPLEX, AND USE OF SAME | PROGENEER INC (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20230390406-A1 | Star Polymer Drug Conjugates | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. | 2023-12-07 | — | — | US | claimed |
| US-20230348903-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2023-11-02 | — | — | US | claimed |
| EP-4228701-A1 | STAR POLYMER DRUG CONJUGATES | Vaccitech North America, Inc. (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2023082821-A1 | SERUM METABOLISM MARKER FOR DIAGNOSING BENIGN AND MALIGNANT PULMONARY NODULES AND USE THEREOF | 上海市第一人民医院 | 2023-05-19 | — | — | WO | claimed |
| CN-115916978-A | Oligonucleotides | 哈德森医学研究所 | 2023-04-04 | — | — | CN | claimed |
| US-20230100429-A1 | LIVE-PATHOGEN-MIMETIC NANOPARTICLES BASED ON PATHOGEN CELL WALL SKELETON, AND PRODUCTION METHOD THEREOF | Progeneer Inc. (KR) | 2023-03-30 | — | — | US | claimed |
| EP-4153751-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2023-03-29 | — | — | EP | claimed |
| CN-115666637-A | Nano particle simulating live pathogen based on pathogen cell wall skeleton and preparation method thereof | 蛋白科技先锋 | 2023-01-31 | — | — | CN | claimed |
| EP-4115901-A1 | LIVE-PATHOGEN-MIMETIC NANOPARTICLES BASED ON PATHOGEN CELL WALL SKELETON, AND PRODUCTION METHOD THEREOF | PROGENEER INC. (KR) | 2023-01-11 | — | — | EP | claimed |
| US-20030119777-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | claimed |
| US-20030096784-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20030096287-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | IONIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20030096286-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20020165189-A1 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| JP-2000510446-A | — | — | 2000-08-15 | — | — | JP | claimed |
| EP-0928290-A4 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2000-01-19 | — | — | EP | claimed |
| EP-0928290-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-07-14 | — | — | EP | claimed |
| US-5898031-A | Oligoribonucleotides for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 1999-04-27 | — | — | US | claimed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100429-A1 | LIVE-PATHOGEN-MIMETIC NANOPARTICLES BASED ON PATHOGEN CELL WALL SKELETON, AND PRODUCTION METHOD THEREOF | TLR8, TLR7, TLR1 | ADORA2A 2115/4885ADORA1 3330/4885PI4KA 513/4885 |
| US-20230390406-A1 | Star Polymer Drug Conjugates | CCND3, CCND2, DRD3 | ADORA2A 1265/4885ADORA1 661/4885PI4KA 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.